THE Australian Competition and Consumer Commission (ACCC) is proposing to deny authorisation for a settlement and licence agreement relating to Revlimid (lenalidomide) and Pomalyst (pomalidomide), under which manufacturer Celgene would allow Juno and Natco to produce generic versions of the medications.
The deal had been set to allow Juno/Natco to supply the generics prior to the expiry of the relevant Celgene patents.
However the ACCC said it was not satisfied the move was in the public interest, with the extent to which it would result in PBS cost savings to the Government "uncertain".
The above article was sent to subscribers in Pharmacy Daily's issue from 25 Mar 22
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Mar 22
